JP2024170587A5 - - Google Patents
Info
- Publication number
- JP2024170587A5 JP2024170587A5 JP2024154766A JP2024154766A JP2024170587A5 JP 2024170587 A5 JP2024170587 A5 JP 2024170587A5 JP 2024154766 A JP2024154766 A JP 2024154766A JP 2024154766 A JP2024154766 A JP 2024154766A JP 2024170587 A5 JP2024170587 A5 JP 2024170587A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- substituted
- carbon atoms
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161491146P | 2011-05-27 | 2011-05-27 | |
| US61/491,146 | 2011-05-27 | ||
| JP2020097905A JP2020147587A (ja) | 2011-05-27 | 2020-06-04 | 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用 |
| JP2022166871A JP7638942B2 (ja) | 2011-05-27 | 2022-10-18 | 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022166871A Division JP7638942B2 (ja) | 2011-05-27 | 2022-10-18 | 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024170587A JP2024170587A (ja) | 2024-12-10 |
| JP2024170587A5 true JP2024170587A5 (https=) | 2025-10-09 |
Family
ID=47259774
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512124A Active JP6581774B2 (ja) | 2011-05-27 | 2012-05-24 | 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法 |
| JP2018026159A Active JP6781721B2 (ja) | 2011-05-27 | 2018-02-16 | 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用 |
| JP2020097905A Pending JP2020147587A (ja) | 2011-05-27 | 2020-06-04 | 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用 |
| JP2022166871A Active JP7638942B2 (ja) | 2011-05-27 | 2022-10-18 | 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用 |
| JP2024154766A Pending JP2024170587A (ja) | 2011-05-27 | 2024-09-09 | 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512124A Active JP6581774B2 (ja) | 2011-05-27 | 2012-05-24 | 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法 |
| JP2018026159A Active JP6781721B2 (ja) | 2011-05-27 | 2018-02-16 | 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用 |
| JP2020097905A Pending JP2020147587A (ja) | 2011-05-27 | 2020-06-04 | 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用 |
| JP2022166871A Active JP7638942B2 (ja) | 2011-05-27 | 2022-10-18 | 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9796754B2 (https=) |
| EP (2) | EP2714684B1 (https=) |
| JP (5) | JP6581774B2 (https=) |
| KR (4) | KR102356286B1 (https=) |
| CN (4) | CN103717595A (https=) |
| AU (4) | AU2012262560B2 (https=) |
| BR (1) | BR112013030372A2 (https=) |
| CA (1) | CA2837586C (https=) |
| CL (1) | CL2013003406A1 (https=) |
| CO (1) | CO6811816A2 (https=) |
| CR (1) | CR20130667A (https=) |
| DK (1) | DK2714684T3 (https=) |
| EA (1) | EA201391756A1 (https=) |
| EC (1) | ECSP13013115A (https=) |
| ES (1) | ES2690993T3 (https=) |
| GT (1) | GT201300295A (https=) |
| IL (3) | IL229505A (https=) |
| MX (1) | MX359217B (https=) |
| NI (1) | NI201300130A (https=) |
| PE (1) | PE20140784A1 (https=) |
| PH (1) | PH12013502461A1 (https=) |
| WO (1) | WO2012166560A1 (https=) |
| ZA (1) | ZA201309654B (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA34521B1 (fr) | 2010-08-17 | 2013-09-02 | Ambrx Inc | Polypeptides de relaxine modifiés et leurs utilisations |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| KR102356286B1 (ko) * | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| KR20140037105A (ko) * | 2011-05-27 | 2014-03-26 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US20130190248A1 (en) * | 2011-07-26 | 2013-07-25 | Agensys, Inc. | Substituted peptide analogs |
| US9981046B2 (en) | 2012-05-15 | 2018-05-29 | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. | Drug-conjugates, conjugation methods, and uses thereof |
| US10800856B2 (en) * | 2012-06-07 | 2020-10-13 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
| SG11201408494UA (en) * | 2012-06-19 | 2015-02-27 | Ambrx Inc | Anti-cd70 antibody drug conjugates |
| US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| CN105283201B (zh) | 2013-03-14 | 2019-08-02 | 斯克利普斯研究所 | 靶向剂抗体偶联物及其用途 |
| EP2968591A1 (en) * | 2013-03-15 | 2016-01-20 | Novartis AG | Cell proliferation inhibitors and conjugates thereof |
| PL2968440T3 (pl) | 2013-03-15 | 2019-12-31 | Zymeworks Inc. | Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania |
| FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| PL2991683T3 (pl) * | 2013-05-02 | 2020-03-31 | Glykos Finland Oy | Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem |
| KR102339240B1 (ko) | 2013-10-15 | 2021-12-15 | 더 스크립스 리서치 인스티튜트 | 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도 |
| ES2826398T3 (es) | 2013-10-15 | 2021-05-18 | Seagen Inc | Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco |
| WO2015057876A1 (en) | 2013-10-15 | 2015-04-23 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| CN103665104B (zh) * | 2013-12-09 | 2015-05-20 | 天津市康信医药科技有限公司 | 一种mmaf中间体五肽的合成方法 |
| BR112016012538A2 (pt) | 2013-12-17 | 2017-09-26 | Novartis Ag | peptídeos citotóxicos e conjugados dos mesmos |
| RU2729194C2 (ru) | 2013-12-27 | 2020-08-05 | Займворкс Инк. | Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов |
| RU2692563C2 (ru) | 2014-04-25 | 2019-06-25 | Пьер Фабр Медикамент | Конъюгат антитела против igf-1r с лекарственным средством и его применение для лечения рака |
| BR112016024363A2 (pt) | 2014-04-25 | 2017-10-10 | Pf Medicament | conjugado de anticorpo-fármaco e seu uso para tratamento de câncer |
| CN106573956A (zh) | 2014-06-13 | 2017-04-19 | 诺华股份有限公司 | 澳瑞他汀衍生物及其缀合物 |
| EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| AU2015318556C1 (en) | 2014-09-17 | 2021-01-07 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| MX2017007169A (es) | 2014-12-03 | 2018-05-02 | Genentech Inc | Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos. |
| EP3250238B1 (en) | 2015-01-28 | 2022-06-01 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
| ES2884844T3 (es) | 2015-03-09 | 2021-12-13 | Agensys Inc | Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3 |
| WO2016154621A1 (en) | 2015-03-26 | 2016-09-29 | The California Institute For Biomedical Research | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF |
| WO2016168773A2 (en) | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
| CN105949277B (zh) * | 2015-05-05 | 2019-03-01 | 成都永泰诺科技有限公司 | 一种抗肿瘤化合物及其用途 |
| JP6486316B2 (ja) | 2015-11-03 | 2019-03-20 | 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 抗体−薬物複合体（ａｄｃ）およびそれを形成するための方法 |
| AU2017213886B2 (en) | 2016-02-04 | 2024-03-07 | The California Institute For Biomedical Research | Humanized anti-CD3 antibodies, conjugates and uses thereof |
| EP3423105B1 (en) | 2016-03-02 | 2021-05-05 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
| KR20180134351A (ko) | 2016-03-25 | 2018-12-18 | 시애틀 지네틱스, 인크. | 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정 |
| CN110267982B (zh) | 2016-10-19 | 2024-02-23 | 斯克利普斯研究所 | 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途 |
| CN110637027B (zh) | 2017-02-08 | 2024-08-30 | 百时美施贵宝公司 | 包含药代动力学增强子的修饰的松弛素多肽及其用途 |
| AU2018237683A1 (en) | 2017-03-24 | 2019-10-31 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
| CN111417408B (zh) * | 2017-11-30 | 2024-04-23 | 思进公司 | 药物接头化合物的制备方法 |
| US12059473B2 (en) | 2018-03-29 | 2024-08-13 | Ambrx, Inc. | Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates |
| CA3103265A1 (en) | 2018-06-12 | 2019-12-19 | Angiex, Inc. | Antibody-oligonucleotide conjugates |
| CN109232712B (zh) * | 2018-08-21 | 2021-08-03 | 联宁（苏州）生物制药有限公司 | 一种用于抗体药物偶联物的中间体的制备方法 |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| WO2020047176A1 (en) | 2018-08-28 | 2020-03-05 | Ambrx, Inc. | Anti-cd3 antibody folate bioconjugates and their uses |
| JP7695885B2 (ja) | 2019-02-12 | 2025-06-19 | アンブルックス，インコーポレイテッド | 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用 |
| US12428477B2 (en) | 2019-02-27 | 2025-09-30 | Angiex, Inc. | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same |
| WO2021032933A1 (en) * | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| WO2021066869A1 (en) | 2019-10-04 | 2021-04-08 | TAE Life Sciences | Antibody compositions comprising fc mutations and site-specific conjugation properties |
| WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| US20230022596A1 (en) * | 2021-06-18 | 2023-01-26 | Clarence Hurt | Neoantigen-eliciting antibody drug conjugates for the immunotherapy of cancer |
| US20240245609A1 (en) * | 2021-07-20 | 2024-07-25 | Novocodex Biopharmaceuticals Co., Ltd. | Freeze-dried composition containing anti-her2 drug conjugate, freeze-dried preparation and preparation method therefor and use thereof |
| MX2024002571A (es) | 2021-09-03 | 2024-03-20 | Toray Industries | Composicion farmaceutica para tratamiento y/o prevencion de cancer. |
| JP2025535713A (ja) | 2022-10-07 | 2025-10-28 | アンブレツクス・インコーポレイテツド | 薬物リンカー及びその抗体コンジュゲート |
| AU2024209360A1 (en) | 2023-01-16 | 2025-09-04 | Ambrx, Inc. | Anti-cd70 antibody-drug conjugates |
| WO2024178310A1 (en) | 2023-02-23 | 2024-08-29 | Ambrx, Inc. | Trop2-directed antibody-drug conjugates and uses thereof |
| WO2024241086A1 (en) | 2023-05-24 | 2024-11-28 | Ambrx, Inc. | Pegylated bovine interferon lambda and methods of use thereof |
| EP4727971A1 (en) | 2023-06-13 | 2026-04-22 | Adcentrx Therapeutics Inc. | Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins |
| IL326709A (en) | 2023-08-22 | 2026-04-01 | Ambrx Inc | Anti-PSMA ADC conjugate compositions and methods of using them |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| CN118754934B (zh) * | 2024-06-05 | 2025-02-07 | 浙江新码生物医药有限公司 | 一种用于制备药物偶联物的毒素衍生物 |
| WO2025264533A1 (en) | 2024-06-17 | 2025-12-26 | Adcentrx Therapeutics Inc. | Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins |
| WO2025262641A1 (en) | 2024-06-19 | 2025-12-26 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| EP0188256B1 (en) | 1985-01-14 | 1991-08-21 | NeoRx | Metal radionuclide labeled proteins for diagnosis and therapy |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US4816444A (en) * | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5831002A (en) | 1992-05-20 | 1998-11-03 | Basf Aktiengesellschaft | Antitumor peptides |
| US5635483A (en) * | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US6034065A (en) * | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5599902A (en) * | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| JP2002505338A (ja) | 1998-03-05 | 2002-02-19 | カイロン コーポレイション | 生物学的に活性な分子の血清半減期を増加するための方法 |
| KR20020022691A (ko) * | 1999-06-08 | 2002-03-27 | 와이즈먼 앤드루 | 아미노옥시기를 포함하는 원자가 플랫폼 분자 |
| US6323315B1 (en) * | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| BR0111726A (pt) | 2000-06-16 | 2003-05-27 | Mitra Medical Technology Ab | Derivados de biotina |
| US7083970B2 (en) | 2001-04-19 | 2006-08-01 | The Scripps Research Institute | Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs |
| US6649402B2 (en) | 2001-06-22 | 2003-11-18 | Wisconsin Alumni Research Foundation | Microfabricated microbial growth assay method and apparatus |
| US6737409B2 (en) * | 2001-07-19 | 2004-05-18 | Hoffmann-La Roche Inc. | Dolastatin 10 derivatives |
| CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| SI1545613T1 (sl) * | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| WO2004058946A2 (en) | 2002-12-22 | 2004-07-15 | The Scripps Research Institute | Protein arrays |
| AU2004213053C1 (en) | 2003-02-20 | 2009-07-16 | Seagen Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| US7498298B2 (en) * | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| CA2567914A1 (en) * | 2004-06-02 | 2005-12-15 | F. Hoffmann-La Roche Ag | Synthesis of amino-alkoxy-heptanoic alkyl ester |
| DK1812031T3 (en) | 2004-11-01 | 2015-09-14 | Univ California | Compositions and methods for the modification of biomolecules |
| NZ565075A (en) * | 2005-06-20 | 2011-05-27 | Psma Dev Company Llc | PSMA antibody-drug conjugates |
| CN104710503B (zh) | 2005-11-08 | 2023-04-25 | Ambrx 公司 | 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂 |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| EP2265283B1 (en) * | 2008-03-18 | 2014-09-03 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| WO2010111018A1 (en) * | 2009-03-06 | 2010-09-30 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
| MX2011010265A (es) * | 2009-04-01 | 2011-10-11 | Genentech Inc | Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso. |
| US8521087B2 (en) | 2009-07-15 | 2013-08-27 | Lg Electronics Inc. | System and method for cognitive radio transmission |
| WO2011038159A2 (en) * | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
| WO2011058188A1 (en) * | 2009-11-16 | 2011-05-19 | Centre National De La Recherche Scientifique - Cnrs - | Compounds and methods for purifying peptides produced by solid phase peptide synthesis |
| HUE045348T2 (hu) * | 2011-05-08 | 2019-12-30 | Legochem Biosciences Inc | Fehérje-hatóanyag konjugátumok és eljárás elõállításukra |
| KR20140037105A (ko) | 2011-05-27 | 2014-03-26 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| KR102356286B1 (ko) | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
-
2012
- 2012-05-24 KR KR1020217026203A patent/KR102356286B1/ko active Active
- 2012-05-24 CN CN201280036296.1A patent/CN103717595A/zh active Pending
- 2012-05-24 CN CN201811251863.0A patent/CN110078788B/zh active Active
- 2012-05-24 PE PE2013002721A patent/PE20140784A1/es not_active Application Discontinuation
- 2012-05-24 BR BR112013030372A patent/BR112013030372A2/pt not_active Application Discontinuation
- 2012-05-24 MX MX2013013683A patent/MX359217B/es active IP Right Grant
- 2012-05-24 EA EA201391756A patent/EA201391756A1/ru unknown
- 2012-05-24 KR KR1020137033072A patent/KR102030856B1/ko active Active
- 2012-05-24 PH PH1/2013/502461A patent/PH12013502461A1/en unknown
- 2012-05-24 WO PCT/US2012/039472 patent/WO2012166560A1/en not_active Ceased
- 2012-05-24 AU AU2012262560A patent/AU2012262560B2/en active Active
- 2012-05-24 KR KR1020197028781A patent/KR102179369B1/ko active Active
- 2012-05-24 US US14/122,672 patent/US9796754B2/en active Active
- 2012-05-24 CN CN202110801039.3A patent/CN113527414A/zh active Pending
- 2012-05-24 EP EP12793246.5A patent/EP2714684B1/en active Active
- 2012-05-24 CN CN201811251860.7A patent/CN110078787A/zh active Pending
- 2012-05-24 EP EP18185522.2A patent/EP3470413A3/en active Pending
- 2012-05-24 CA CA2837586A patent/CA2837586C/en active Active
- 2012-05-24 KR KR1020207032063A patent/KR20200128601A/ko not_active Ceased
- 2012-05-24 ES ES12793246.5T patent/ES2690993T3/es active Active
- 2012-05-24 DK DK12793246.5T patent/DK2714684T3/en active
- 2012-05-24 JP JP2014512124A patent/JP6581774B2/ja active Active
-
2013
- 2013-11-19 IL IL229505A patent/IL229505A/en active IP Right Grant
- 2013-11-25 GT GT201300295A patent/GT201300295A/es unknown
- 2013-11-26 NI NI201300130A patent/NI201300130A/es unknown
- 2013-11-27 CL CL2013003406A patent/CL2013003406A1/es unknown
- 2013-11-28 CO CO13280266A patent/CO6811816A2/es unknown
- 2013-12-17 CR CR20130667A patent/CR20130667A/es unknown
- 2013-12-20 ZA ZA2013/09654A patent/ZA201309654B/en unknown
- 2013-12-26 EC ECSP13013115 patent/ECSP13013115A/es unknown
-
2016
- 2016-06-28 AU AU2016204454A patent/AU2016204454B2/en active Active
-
2017
- 2017-09-12 US US15/702,682 patent/US10954270B2/en active Active
- 2017-10-03 IL IL254879A patent/IL254879B/en active IP Right Grant
-
2018
- 2018-02-16 JP JP2018026159A patent/JP6781721B2/ja active Active
- 2018-05-23 AU AU2018203639A patent/AU2018203639B2/en active Active
-
2020
- 2020-04-23 IL IL274204A patent/IL274204B/en unknown
- 2020-06-04 JP JP2020097905A patent/JP2020147587A/ja active Pending
- 2020-08-11 AU AU2020217337A patent/AU2020217337B2/en active Active
-
2021
- 2021-01-05 US US17/142,169 patent/US11420999B2/en active Active
-
2022
- 2022-04-28 US US17/732,285 patent/US20220411469A1/en active Pending
- 2022-10-18 JP JP2022166871A patent/JP7638942B2/ja active Active
-
2024
- 2024-09-09 JP JP2024154766A patent/JP2024170587A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024170587A5 (https=) | ||
| JP2024127887A5 (https=) | ||
| JP2021523225A5 (https=) | ||
| JPWO2022235870A5 (https=) | ||
| RU2002131941A (ru) | 3-азот-6,7-дикислородсодержащие стероиды и их применение | |
| JPWO2022060836A5 (https=) | ||
| US20110039933A1 (en) | S1p-1 receptor agonists | |
| CN1215397A (zh) | 具有免疫调解剂作用的酰化n－羟甲基酞胺哌啶酮－前药 | |
| JPWO2021187531A5 (https=) | ||
| JP4393376B2 (ja) | フェニルシクロヘキシルプロパノールアミン誘導体、その製造法、およびその治療的適用 | |
| JP2021529159A5 (https=) | ||
| JP2003503488A5 (https=) | ||
| HK62397A (en) | 3.3'-dithiobis (propionic acids) and esters thereof | |
| JP5147393B2 (ja) | 化学化合物ｉ | |
| WO2016078582A1 (zh) | 新型核苷氨基磷酸酯衍生物及其应用 | |
| JPWO2021216195A5 (https=) | ||
| JP2001522835A (ja) | フェニル−アルキル−イミダゾール型のｈ３レセプターリガンド | |
| JP2020529472A5 (https=) | ||
| JPWO2020257870A5 (https=) | ||
| JPH1135559A (ja) | フタルイミド誘導体及びそれら誘導体を含んでなる医薬 | |
| JPWO2020214728A5 (https=) | ||
| JP2007513113A (ja) | 抗高血圧薬剤のニトロオキシ誘導体 | |
| JPS589093B2 (ja) | 動物用抗ビ−ルス剤 | |
| JPWO2023177877A5 (https=) | ||
| JPWO2023129956A5 (https=) |